MT228: Phase I started

Eisai's Morphotek Inc. subsidiary began an open-label, dose-escalation, U.S. Phase I trial to evaluate intralesional MORAb-028 for three 5-day courses over a 30-day cycle in 18 patients. Morphotek li...